Novo Nordisk CEO Lars Fruergaard Jørgensen’s fear, as reported by WIRED in January 2025, is not that an insulin shortage has already happened. It is that pressure on insulin prices and the economics of drug distribution could make the business of supplying insulin less viable just as Novo is committing manufacturing capacity to fast-growing semaglutide medicines such as Ozempic and Wegovy. The concern is about incentives and future capacity—and about how a company balances patient needs against commercial pressures.
What Jørgensen said he fears
In Virginia Heffernan’s January 13, 2025, WIRED feature, Jørgensen warns that continued pressure on insulin economics could eventually threaten the incentive to keep supplying it. “If this persists, the economics around insulin could be no longer viable. That scares the hell out of me.” Read the WIRED feature.
That is a warning about a possible future risk, not a report that insulin supply has already failed or that a near-term shortage is certain. The feature’s central tension is that insulin remains essential to people who depend on it, while semaglutide has become a major growth engine whose production also requires resources.
Why the Ozempic boom is part of an insulin story
Semaglutide created new demand and manufacturing pressure
Ozempic and Wegovy contain semaglutide, a GLP-1 analogue. WIRED describes Ozempic as a medicine used for type 2 diabetes and Wegovy as a higher-dose semaglutide product for weight loss. The feature says these medicines do not generally meet the needs of people with type 1 diabetes, for whom insulin remains central to treatment. These are descriptions in a 2025 feature, not a substitute for current regulator labeling or medical advice.
#1 Best Overall
WIRED portrays Novo as managing demand for semaglutide while trying to preserve its role in insulin. Manufacturing capacity is not instantly expandable: the feature reports that building and bringing a facility online can cost $2 billion to $3 billion and take about five years. Those figures are the article’s reported estimate, not a universal price or construction timeline for every facility.
Insulin and semaglutide have different financial stakes
The company’s public identity and history are closely tied to insulin, while much of its recent growth has been associated with semaglutide. WIRED reported that Novo Nordisk’s market capitalization reached $424 billion in 2023. That historical valuation helps explain the scale of the company’s success, but it does not by itself establish how much money any particular medicine earns or how much capacity is available for insulin.
The same feature reported that roughly 15 million people in the United States used semaglutide medicines, as stated in its account. That is a figure from WIRED’s January 2025 feature, not a current 2026 usage estimate, and it does not distinguish the share using Ozempic from other semaglutide products.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
How US drug pricing enters the argument
Jørgensen’s concern is partly about the gap between what a manufacturer receives and the money that moves through the US drug-payment system. WIRED attributes to him the estimate that 74 cents of each dollar Novo received from US insulin sales went to pharmacy benefit managers, wholesalers, and insurers. This is his attributed figure as reported by the feature, not an independently established breakdown of every insulin transaction or a claim that every patient pays the same amount.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Scan for outdated or missing drivers - takes under a minute3Repair Windows errors before they cause bigger problemsThe distinction matters for personal finances: the price visible to a patient at the pharmacy, the amount negotiated or paid by an insurer, and the revenue a manufacturer receives are not necessarily the same figure. The feature’s argument is that payment structures and intermediaries affect the economics around insulin; it does not provide an individual patient’s out-of-pocket price, insurance terms, or savings estimate.
Jørgensen also told WIRED, “We at Novo Nordisk don’t decide what patients pay.” The statement describes the company’s position on patient prices, but it does not remove the manufacturer from the broader system of pricing, negotiation, and supply decisions discussed in the article.
What the reported figures do—and do not—show
| Figure | What WIRED reported | How to read it |
|---|---|---|
| 8.4 million | People worldwide with type 1 diabetes, as reported in the 2025 feature. | A global figure in WIRED’s account, not a count of people affected by an insulin shortage. |
| Roughly 15 million | US semaglutide users, as stated in the feature’s account. | A historical article-reported figure, not a current usage count or an Ozempic-only total. |
| $424 billion | Novo Nordisk’s market capitalization in 2023, according to WIRED. | A company valuation at a past point in time, not cash available for manufacturing. |
| $3.6 billion; $2.3 billion | Novo Nordisk’s global income taxes paid in 2023, with $2.3 billion going to Denmark, as reported by WIRED. | Historical company tax figures; they do not measure the profitability or cost of insulin alone. |
| 74 cents per dollar | The share of each dollar Novo received from US insulin sales that Jørgensen said went to pharmacy benefit managers, wholesalers, and insurers. | An attributed statement in the feature, not a universal patient-price formula. |
| $2 billion to $3 billion; about five years | WIRED’s reported cost and time to build and bring a manufacturing facility online. | An estimate reported by the feature, not a guarantee for every project. |
All figures in this table come from Virginia Heffernan’s January 2025 WIRED feature and should be read with those dates and attributions, rather than as current market data.
Why supply capacity is a long-term financial question
A large company valuation does not automatically translate into immediate production capacity. If a facility takes years and billions of dollars to bring online, choices about investment and which products use existing capacity can have consequences well beyond a single quarter. WIRED presents this as the structural backdrop to Jørgensen’s concern: continued pressure on insulin economics could make future supply investment harder to justify while demand for other medicines competes for resources.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteThe feature does not establish that Novo has shifted capacity away from insulin, quantify how much capacity is allocated to each product, or forecast a specific shortage. Its point is narrower: the economics of a medicine can affect whether a manufacturer has a commercial reason to sustain or expand supply over time.
Rank #4
The responsibility Novo says it carries
The feature places the company’s commercial responsibilities alongside its stated purpose and its relationship with insulin-dependent patients. WIRED reported that Novo Nordisk paid $3.6 billion in global income taxes in 2023, including $2.3 billion to Denmark, and describes the company’s scale and economic importance. Those figures illustrate the company’s size; they do not settle what it owes patients or how it should allocate production.
The human stakes are not abstract. Erik Hageman, a longtime insulin user quoted by WIRED, described what he associates with going without treatment: “I’d be blind and I’d have to cut off my legs and have kidney failure.” His statement conveys the gravity of insulin dependence; it is not a clinical prediction about every person who misses insulin.
WIRED leaves the conflict unresolved. Its account does not offer a simple answer for how Novo should reconcile patient reliance on insulin with investment demands, competition, and shareholder expectations.
Free tools Windows power users keep installed
One-click scans. No signup required.
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
How to interpret the article now
The feature is a January 2025 snapshot. Its discussion of late-2024 events, named leaders, policy proposals, market conditions, and product availability belongs to that period unless verified against newer sources. The figures above should not be used as current estimates of market capitalization, patient use, pricing, supply, or facility plans.
For readers concerned about their own insulin access or costs, the WIRED feature is not a source of individualized pricing or treatment guidance. Current coverage and cost depend on a person’s product, insurer, pharmacy, and location; clinical decisions should be discussed with a qualified clinician.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
